Acción 4523 EISAI CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Eisai Co., Ltd.

Acciones

4523

JP3160400002

Diferido Japan Exchange
Otros sitios de cotización
 03:43:03 08/05/2024 		Varia. Cinco días. Varia. 1 de enero.
6.617 JPY +0,33 % Gráfico intradía de Eisai Co., Ltd. +0,99 % -6,21 %
07/05 Panel de la FDA discutirá el 10 de junio un fármaco de Eli Lilly contra el Alzheimer RE
06/05 Las personas con dos copias de un gen de riesgo tienen una forma genética de Alzheimer, según los científicos RE

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
People with two copies of a risk gene have genetic form of Alzheimer's, scientists say
BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Alzheimer's drug adoption in US slowed by doctors' skepticism
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 4523
  4. Noticias Eisai Co., Ltd.
  5. Otros idiomas